Though 2012 was arguably a good year for companies that develop and sell microarrays, with experts advocating their use as a first-tier test for invasive prenatal diagnostics and several organizations relying on arrays to support new genetic genealogy offerings, the news event that garnered the most interest among BioArray News readers in the past twelve months occurred in early June, when Roche decided to shutter most of the activities of its Madison, Wis.-based NimbleGen array business.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.